TLR9 and COVID-19: In this study, we sought to deliver RBD antigen using a nanoparticle delivery system with CpG55.2 oligonucleotide adjuvant (TLR-9 agonist) to achieve a novel needle-free, mucosally delivered, COVID-19 vaccine.